Corticosteroids and circadian rhythms in the cardiovascular system
Copyright © 2021. Published by Elsevier Ltd..
The mineralocorticoid receptor (MR) plays a central role in cardiac physiological function and disease and is thus an attractive therapeutic target for patients with heart failure. However, the incidence of significant side effects from mineralocorticoid receptor antagonist (MRA) treatment has led to investigation of new mechanisms that may enhance MR targeted therapies. Recent studies have identified the circadian clock as a novel, reciprocal interacting partner of the MR in the heart. While the closely related glucocorticoid receptor (GR) and its ligand, cortisol (corticosterone in rodents), are established regulators of the circadian clock, new data suggest that the MR can also regulate circadian clock gene expression and timing. This review will discuss the role of the MR and its ligands in the regulation of the circadian clock in the heart and the implications of dysregulation of these systems for cardiac disease progression, and for MR activation.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:57 |
---|---|
Enthalten in: |
Current opinion in pharmacology - 57(2021) vom: 20. Apr., Seite 21-27 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Kanki, Monica [VerfasserIn] |
---|
Links: |
---|
Themen: |
Adrenal Cortex Hormones |
---|
Anmerkungen: |
Date Completed 25.10.2021 Date Revised 25.10.2021 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.coph.2020.10.007 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM317744755 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM317744755 | ||
003 | DE-627 | ||
005 | 20231225163918.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.coph.2020.10.007 |2 doi | |
028 | 5 | 2 | |a pubmed24n1059.xml |
035 | |a (DE-627)NLM317744755 | ||
035 | |a (NLM)33207294 | ||
035 | |a (PII)S1471-4892(20)30105-3 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Kanki, Monica |e verfasserin |4 aut | |
245 | 1 | 0 | |a Corticosteroids and circadian rhythms in the cardiovascular system |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 25.10.2021 | ||
500 | |a Date Revised 25.10.2021 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2021. Published by Elsevier Ltd. | ||
520 | |a The mineralocorticoid receptor (MR) plays a central role in cardiac physiological function and disease and is thus an attractive therapeutic target for patients with heart failure. However, the incidence of significant side effects from mineralocorticoid receptor antagonist (MRA) treatment has led to investigation of new mechanisms that may enhance MR targeted therapies. Recent studies have identified the circadian clock as a novel, reciprocal interacting partner of the MR in the heart. While the closely related glucocorticoid receptor (GR) and its ligand, cortisol (corticosterone in rodents), are established regulators of the circadian clock, new data suggest that the MR can also regulate circadian clock gene expression and timing. This review will discuss the role of the MR and its ligands in the regulation of the circadian clock in the heart and the implications of dysregulation of these systems for cardiac disease progression, and for MR activation | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a Review | |
650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
650 | 7 | |a Mineralocorticoid Receptor Antagonists |2 NLM | |
650 | 7 | |a Receptors, Glucocorticoid |2 NLM | |
650 | 7 | |a Receptors, Mineralocorticoid |2 NLM | |
700 | 1 | |a Young, Morag J |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Current opinion in pharmacology |d 2001 |g 57(2021) vom: 20. Apr., Seite 21-27 |w (DE-627)NLM116029935 |x 1471-4973 |7 nnns |
773 | 1 | 8 | |g volume:57 |g year:2021 |g day:20 |g month:04 |g pages:21-27 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.coph.2020.10.007 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 57 |j 2021 |b 20 |c 04 |h 21-27 |